{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:29:27Z","timestamp":1767979767662,"version":"3.49.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2011,1,26]],"date-time":"2011-01-26T00:00:00Z","timestamp":1296000000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0016031","type":"journal-article","created":{"date-parts":[[2011,1,26]],"date-time":"2011-01-26T21:42:42Z","timestamp":1296078162000},"page":"e16031","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors"],"prefix":"10.1371","volume":"6","author":[{"given":"Charles W.","family":"Kanaly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit I.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony F.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Crocker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan H.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darell D.","family":"Bigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2011,1,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1200\/JCO.2006.06.5599","article-title":"Measures of response: RECIST, WHO, and new alternatives.","volume":"24","author":"CC Jaffe","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/ncponc1204","article-title":"Response criteria for glioma.","volume":"5","author":"AG Sorensen","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1148\/rg.282075068","article-title":"Radiologic measurements of tumor response to treatment: practical approaches and limitations.","volume":"28","author":"C Suzuki","year":"2008","journal-title":"Radiographics"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma.","volume":"8","author":"DR Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"P Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.","volume":"28","author":"PY Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","article-title":"Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.","volume":"9","author":"D Brandsma","year":"2008","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1200\/JCO.2009.22.4998","article-title":"End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald&apos;s Criteria.","volume":"27","author":"MJ van den Bent","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1212\/WNL.48.5.1336","article-title":"Chemotherapy response criteria in malignant glioma.","volume":"48","author":"R Grant","year":"1997","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1215\/15228517-2007-062","article-title":"Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.","volume":"10","author":"KR Lamborn","year":"2008","journal-title":"Neuro Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1215\/15228517-2006-025","article-title":"The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.","volume":"9","author":"KV Ballman","year":"2007","journal-title":"Neuro Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2001.19.2.551","article-title":"Comparison of diameter and perimeter methods for tumor volume calculation.","volume":"19","author":"AG Sorensen","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref14","article-title":"Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM). Central Nervous System Tumors","author":"R Lai","year":"2010"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nm.1919","article-title":"The parametric response map is an imaging biomarker for early cancer treatment outcome.","volume":"15","author":"CJ Galban","year":"2009","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1073\/pnas.0508347102","article-title":"Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.","volume":"102","author":"DA Hamstra","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1200\/JCO.2007.15.2363","article-title":"Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival.","volume":"26","author":"DA Hamstra","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1073\/pnas.0501532102","article-title":"Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response.","volume":"102","author":"BA Moffat","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref19","first-page":"581","article-title":"Evaluation of cancer therapy using diffusion magnetic resonance imaging.","volume":"2","author":"BD Ross","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1200\/JCO.2000.18.10.2179","article-title":"Evaluation of tumor measurements in oncology: use of film-based and electronic techniques.","volume":"18","author":"LH Schwartz","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00330-005-0036-x","article-title":"Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria.","volume":"16","author":"K Marten","year":"2006","journal-title":"Eur Radiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11547-006-0035-2","article-title":"Volumetric evaluation of therapy response in patients with lung metastases. Preliminary results with a computer system (CAD) and comparison with unidimensional measurements.","volume":"111","author":"F Fraioli","year":"2006","journal-title":"Radiol Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1109\/42.700731","article-title":"Automatic tumor segmentation using knowledge-based techniques.","volume":"17","author":"MC Clark","year":"1998","journal-title":"IEEE Trans Med Imaging"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0730-725X(97)00302-0","article-title":"MRI measurement of brain tumor response: comparison of visual metric and automatic segmentation.","volume":"16","author":"LP Clarke","year":"1998","journal-title":"Magn Reson Imaging"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.acra.2004.05.020","article-title":"Segmentation of tumors in magnetic resonance brain images using an interactive multiscale watershed algorithm.","volume":"11","author":"MM Letteboer","year":"2004","journal-title":"Acad Radiol"},{"key":"ref26","first-page":"770","article-title":"Measurement of tumor \u201csize\u201d in recurrent malignant glioma: 1D, 2D, or 3D?","volume":"26","author":"MF Dempsey","year":"2005","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1215\/15228517-2005-005","article-title":"Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods.","volume":"8","author":"E Galanis","year":"2006","journal-title":"Neuro Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1215\/S1522851705000529","article-title":"Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas.","volume":"8","author":"GD Shah","year":"2006","journal-title":"Neuro Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/jnci\/93.18.1401","article-title":"Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors.","volume":"93","author":"KE Warren","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.acra.2004.09.004","article-title":"Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography.","volume":"11","author":"LN Tran","year":"2004","journal-title":"Acad Radiol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1259\/bjr.73.875.11144795","article-title":"CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size.","volume":"73","author":"SA Sohaib","year":"2000","journal-title":"Br J Radiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1148\/radiology.213.3.r99dc01881","article-title":"Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach.","volume":"213","author":"U Fischer","year":"1999","journal-title":"Radiology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejrad.2008.03.021","article-title":"Assessment of breast cancer response to neoadjuvant chemotherapy: is volumetric MRI a reliable tool?","volume":"71","author":"M Lorenzon","year":"2009","journal-title":"Eur J Radiol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijrobp.2007.10.055","article-title":"Correlation of positron emission tomography standard uptake value and pathologic specimen size in cancer of the head and neck.","volume":"71","author":"RJ Burri","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2505::AID-CNCR24>3.0.CO;2-F","article-title":"Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding.","volume":"80","author":"YE Erdi","year":"1997","journal-title":"Cancer"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijrobp.2006.10.010","article-title":"Effect of bevacizumab on radiation necrosis of the brain.","volume":"67","author":"J Gonzalez","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11060-008-9573-x","article-title":"Time course of imaging changes of GBM during extended bevacizumab treatment.","volume":"88","author":"S Ananthnarayan","year":"2008","journal-title":"J Neurooncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1212\/01.wnl.0000208958.29600.87","article-title":"MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.","volume":"66","author":"WB Pope","year":"2006","journal-title":"Neurology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ccr.2006.12.008","article-title":"Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers.","volume":"11","author":"A Hormigo","year":"2007","journal-title":"Cancer Cell"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.","volume":"26","author":"AA Brandes","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1215\/15228517-2008-008","article-title":"Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.","volume":"10","author":"AA Brandes","year":"2008","journal-title":"Neuro Oncol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1212\/01.WNL.0000133398.11870.9A","article-title":"Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.","volume":"63","author":"MC de Wit","year":"2004","journal-title":"Neurology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0016031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T04:18:04Z","timestamp":1559967484000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0016031"}},"subtitle":[],"editor":[{"given":"Maciej","family":"Lesniak","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,1,26]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0016031","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,26]]}}}